Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Liu

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|August 31, 2023
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice PerspectiveChristopher Yasenchak, Nicholas Liu, April Beeks, et al.
Organic Letters|June 14, 2017
Identification and Heterologous Production of a Benzoyl-Primed Tricarboxylic Acid Polyketide Intermediate from the Zaragozic Acid A Biosynthetic PathwayNicholas Liu, Yiu-Sun Hung, Shu-Shan Gao, et al.
Leukemia & Lymphoma|April 19, 2023
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trialTycel Phillips, Kristen Migliaccio-Walle, Kristina S Yu, et al.
Journal of the American Chemical Society|April 15, 2021
Targeted Genome Mining Reveals the Biosynthetic Gene Clusters of Natural Product CYP51 InhibitorsNicholas Liu, Elizabeth D Abramyan, Wei Cheng, et al.
The Oncologist|March 27, 2023
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and ChemotherapyJohn M Burke, Nicholas Liu, Kristina S Yu, et al.
Nature Chemical Biology|October 25, 2016
Structural basis of nonribosomal peptide macrocyclization in fungiJinru Zhang, Nicholas Liu, Ralph A Cacho, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims AnalysisDahlia Sano, Nicholas Liu, Scott Knowles, et al.
Journal of Autism and Developmental Disorders|June 16, 2021
Concerns About ABA-Based Intervention: An Evaluation and RecommendationsJustin B Leaf, Joseph H Cihon, Ronald Leaf, et al.
Journal of Autism and Developmental Disorders|July 21, 2021
Correction to: Concerns About ABA-Based Intervention: An Evaluation and RecommendationsJustin B Leaf, Joseph H Cihon, Ronald Leaf, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 2, 2023
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United StatesStefan K Barta, Nicholas Liu, Maral DerSarkissian, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|August 31, 2023
Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice PerspectiveChristopher Yasenchak, Nicholas Liu, April Beeks, et al.
Organic Letters|June 14, 2017
Identification and Heterologous Production of a Benzoyl-Primed Tricarboxylic Acid Polyketide Intermediate from the Zaragozic Acid A Biosynthetic PathwayNicholas Liu, Yiu-Sun Hung, Shu-Shan Gao, et al.
Leukemia & Lymphoma|April 19, 2023
Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trialTycel Phillips, Kristen Migliaccio-Walle, Kristina S Yu, et al.
Journal of the American Chemical Society|April 15, 2021
Targeted Genome Mining Reveals the Biosynthetic Gene Clusters of Natural Product CYP51 InhibitorsNicholas Liu, Elizabeth D Abramyan, Wei Cheng, et al.
The Oncologist|March 27, 2023
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and ChemotherapyJohn M Burke, Nicholas Liu, Kristina S Yu, et al.
Nature Chemical Biology|October 25, 2016
Structural basis of nonribosomal peptide macrocyclization in fungiJinru Zhang, Nicholas Liu, Ralph A Cacho, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims AnalysisDahlia Sano, Nicholas Liu, Scott Knowles, et al.
Journal of Autism and Developmental Disorders|June 16, 2021
Concerns About ABA-Based Intervention: An Evaluation and RecommendationsJustin B Leaf, Joseph H Cihon, Ronald Leaf, et al.
Journal of Autism and Developmental Disorders|July 21, 2021
Correction to: Concerns About ABA-Based Intervention: An Evaluation and RecommendationsJustin B Leaf, Joseph H Cihon, Ronald Leaf, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 2, 2023
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United StatesStefan K Barta, Nicholas Liu, Maral DerSarkissian, et al.
Pageof 3